177Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer

Eyben, Finn Edler von; Kiljunen, Timo; Joensuu, Timo; Kairemo, Kalevi; Uprimny, Christian; Virgolini, Irene

doi:10.18632/oncotarget.19805

Cited by 16 publications

(16 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussionsupporting

confidence: 92%

“…These findings supported the promising results indicated in two previous papers [4, 5]. As to a previous case report [4], the present study incorporates an additional 44 patients with predominant LNM. As to a previous report of 19 patients with LNM treated at the Zentralklinik Bad Berka, Germany 2017 [5], the present study reported a longer follow-up to September/October 2018 and added patients treated at an Austrian, a Turkish, and two Australian centers.…”

Section: Discussionsupporting

confidence: 92%

“…In addition, two studies reported encouraging findings as LuPRLT was given to 20 patients who only had lymph node metastases (LNM) of prostate cancer (PC) [4, 5]. The present study reports a longer follow-up of the 20 patients and expanded the number of patients to a total of 45 patients with predominant LNM with or without one or two bone metastases.…”

Section: Introductionmentioning

confidence: 64%

See 2 more Smart Citations

177Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer

et al. 2019

Self Cite

View full text Add to dashboard Cite

177 Lu-PSMA radioligand therapy (LuPRLT) is mainly used for patients with metastatic castration-resistant prostate cancer who are resistant to established drugs. This study describes LuPRLT, either LuPSMA I&T or LuPSMA RLT-617, for 45 patients with predominant lymph node metastatic prostate cancer (LNM PC). Thirtyfive patients had LNM and ten patients had LNM and one or two bone metastases. Before LuPRLT, the patients had prostate specific antigen (PSA) of median 18 µg/l (interquartile range (IQR): 3.3-39). LuPRLT was given with a cumulative injected 177 Lu activity of median 14.5 GBq (IQR: 12.2-20.4). Maximum percentage decline of PSA was median 92% (IQR: 70-99). Thirty-five patients with only LNM had a better overall survival (OS) than ten patients with LNM and one or two bone metastases. Thirty-three docetaxel-naïve patients had a longer PSMA PET/CT progression-free survival than twelve patients who were resistant to docetaxel. Twenty-two patients who received LuPRLT with a cumulative injected 177 Lu activity ≥ 14.8 GBq had a better PSMA PET/CT progression-free survival than 23 patients who received LuPRLT with a lower cumulative injected 177 Lu activity. Seventeen patients with relapse after LuPRLT who received rechallenge LuPRLT or ActPRLT had a better OS than five patients who received other forms for relapse treatment. LuPRLT gave mild and transitory adverse effects. The findings of the present study suggest that LuPRLT of patients with LNM may be effective and safe. The promising results motivate randomized phase II trials to further quantify the impact of LuPRLT as treatment of patients with LNM.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 64%

See 1 more Smart Citation

177Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…But in our review, 177 Lu-PSMA RLT was more effective than third-line treatment despite being given later in the treatment sequence for mCRPC. Correspondingly, 177 Lu-PSMA-617 RLT gave better PSA decline than abiraterone in a recent case report [ 18 ].…”

Section: Discussionmentioning

confidence: 96%

“…117 Lu-PSMA RLT is mainly used as a compassionate treatment of patients with end-stage mCRPC [ 17 ]. For a patient with only lymph node metastatic CRPC, 177 Lu-PSMA-617 RLT reduced PSA more than salvage radiotherapy and abiraterone [ 18 ]. In contrast, APCCC 2017 did not refer to 177 Lu-PSMA RLT [ 19 ].…”

Section: Introductionmentioning

confidence: 99%

Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review

Eyben

Roviello

Kiljunen

et al. 2017

Eur J Nucl Med Mol Imaging

Self Cite

156

View full text Add to dashboard Cite

AimsThere is a controversy as to the relative efficacy of 177Lu prostate specific membrane antigen (PSMA) radioligand therapy (RLT) and third-line treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The aim of our systematic review was to elucidate whether 177Lu-PSMA RLT and third-line treatment have similar effects and adverse effects (PROSPERO ID CRD42017067743).MethodsThe review followed Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Searches in Pubmed and Embase selected articles up to September 2017. A search in ClinicalTrials.gov indicated ongoing studies. The meta-analysis used the random-effects model.ResultsTwelve studies including 669 patients reported 177Lu-PSMA RLT. Overall, 43% of the patients had a maximum decline of PSA of ≥50% following treatment with 177Lu-PSMA RLT. The treatment with 177Lu-PSMA-617 and 177Lu-PSMA for imaging and therapy (I&T) had mainly transient adverse effects. Sixteen studies including 1338 patients reported third-line treatment. Overall, 21% of the patients had a best decline of PSA of ≥50% following third-line treatment. After third-line treatment with enzalutamide and cabazitaxel, adverse effects caused discontinuation of treatment for 10% to 23% of the patients. 177Lu-PSMA RLT gave a best PSA decline ≥50% more often than third-line treatment (mean 44% versus 22%, p = 0.0002, t test). 177Lu-PSMA RLT gave objective remission more often than third-line treatment (overall 31 of 109 patients versus 43 of 275 patients, p = 0.004, χ2 test). Median survival was longer after 177Lu-PSMA RLT than after third-line treatment, but the difference was not statistically significant (mean 14 months versus 12 months, p = 0.32, t test). Adverse effects caused discontinuation of treatment more often for third-line treatment than for 177Lu-PSMA RLT (22 of 66 patients versus 0 of 469 patients, p < 0.001, χ2 test).ConclusionsAs for patients with mCRPC, treatment with 177Lu-PSMA-617 RTL and 177Lu-PSMA I&T gave better effects and caused fewer adverse effects than third-line treatment.

show abstract

Radiopharmaceutical Sciences

Neumaier

Benešová

Hugenberg

et al. 2020

Clinical Nuclear Medicine

View full text Add to dashboard Cite

177Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer

Cited by 16 publications

References 13 publications

177Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer

177Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer

Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review

Radiopharmaceutical Sciences

Contact Info

Product

Resources

About